How CREBBP changes drive B‑cell (follicular) lymphoma and ways to target them
Identifying/Targeting Mechanisms of Lymphomagenesis Driven by CREBBP Inactivation
Working on treatments to reverse the effects of CREBBP mutations for people with follicular and other B‑cell lymphomas.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11322104 on NIH RePORTER |
What this research studies
Researchers are using mouse models and gene‑edited lymphoma cells to see how common CREBBP mutations change the way genes are turned on in germinal center B‑cells. They study chemical tags on chromatin (like loss of H3K27 acetylation and gain of H3K27 methylation) that silence enhancers and help tumors grow. The team compares different mutation types and probes how CREBBP interacts with other proteins (for example BCL6, HDAC3, EZH2) to find molecular points that can be drugged. These lab findings aim to point toward strategies that could be tested later in patients.
Who could benefit from this research
Good fit: Ideal candidates would be people with follicular or related B‑cell lymphomas whose tumors carry CREBBP mutations or who are interested in donating tumor samples for research.
Not a fit: Patients without CREBBP mutations or with unrelated non‑B‑cell cancers are unlikely to benefit directly from this specific line of research.
Why it matters
Potential benefit: If successful, this work could point to new targeted therapies that restore normal gene regulation and improve treatment options for patients with CREBBP‑mutant follicular or other B‑cell lymphomas.
How similar studies have performed: Prior research has shown that targeting epigenetic regulators (for example EZH2 inhibitors) can help some lymphomas, but approaches specifically directed at CREBBP mutation effects are relatively new and early stage.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Green, Michael Richard — University of Tx Md Anderson Can Ctr
- Study coordinator: Green, Michael Richard
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.